Serum butyrylcholinesterase and zinc in breast cancer

Rupesh Kumar, Sairoz Razab, Krishnananda Prabhu, Satadru Ray, Bhanu Prakash

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Context: Even though, a large number of serological, molecular markers have been proposed for breast cancer screening, most of them lack specificity, sensitivity, prognostic value, and cost effectiveness. Butyrylcholinesterase (BChE) and its genes are aberrantly expressed in a variety of human cancers. It has-been linked to tumorigenesis, cell proliferation, and cell differentiation. Zinc (Zn) is a cofactor for superoxide dismutase, an enzyme that protects cellular components against free radical-induced damage and carcinogenesis. Therefore, the aim of present study was to estimate and compare serum BChE and serum Zn levels in healthy controls and biopsy proven breast cancer patients before definitive therapy. Aims: To estimate and compare serum BChE and serum Zn levels in healthy controls and biopsy proven breast cancer patients before definitive therapy. Settings and Design: Serum BChE and Zn were estimated in 46 newly diagnosed (preoperative) female patients with breast cancer and 50 healthy female volunteers. Subjects and Methods: Serum BChE and Zn were estimated by spectrophotometric method. Statistical Analysis Used: Data was expressed as median and inter quartile range. Comparisons between different stages of cancer were done using Kruskal-Wallis test. Results: There was a significant increase in serum BChE and Zn in breast cancer patients compared to controls (P < 0.001). Serum BChE showed a significant increase and Zn was significantly decreased in different stages of breast cancer. Conclusions: Both BChE and Zn are inexpensive and can easily be analyzed and may play a role in the management of breast cancer.

Original languageEnglish
Pages (from-to)367-370
Number of pages4
JournalJournal of Cancer Research and Therapeutics
Volume13
Issue number2
DOIs
Publication statusPublished - 01-04-2017

Fingerprint

Butyrylcholinesterase
Zinc
Breast Neoplasms
Serum
Carcinogenesis
Biopsy
Statistical Data Interpretation
Early Detection of Cancer
Superoxide Dismutase
Free Radicals
Cost-Benefit Analysis
Cell Differentiation
Neoplasms
Healthy Volunteers
Cell Proliferation
Sensitivity and Specificity

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Kumar, Rupesh ; Razab, Sairoz ; Prabhu, Krishnananda ; Ray, Satadru ; Prakash, Bhanu. / Serum butyrylcholinesterase and zinc in breast cancer. In: Journal of Cancer Research and Therapeutics. 2017 ; Vol. 13, No. 2. pp. 367-370.
@article{a679aa504ce140aba0ed5f5829c79a4f,
title = "Serum butyrylcholinesterase and zinc in breast cancer",
abstract = "Context: Even though, a large number of serological, molecular markers have been proposed for breast cancer screening, most of them lack specificity, sensitivity, prognostic value, and cost effectiveness. Butyrylcholinesterase (BChE) and its genes are aberrantly expressed in a variety of human cancers. It has-been linked to tumorigenesis, cell proliferation, and cell differentiation. Zinc (Zn) is a cofactor for superoxide dismutase, an enzyme that protects cellular components against free radical-induced damage and carcinogenesis. Therefore, the aim of present study was to estimate and compare serum BChE and serum Zn levels in healthy controls and biopsy proven breast cancer patients before definitive therapy. Aims: To estimate and compare serum BChE and serum Zn levels in healthy controls and biopsy proven breast cancer patients before definitive therapy. Settings and Design: Serum BChE and Zn were estimated in 46 newly diagnosed (preoperative) female patients with breast cancer and 50 healthy female volunteers. Subjects and Methods: Serum BChE and Zn were estimated by spectrophotometric method. Statistical Analysis Used: Data was expressed as median and inter quartile range. Comparisons between different stages of cancer were done using Kruskal-Wallis test. Results: There was a significant increase in serum BChE and Zn in breast cancer patients compared to controls (P < 0.001). Serum BChE showed a significant increase and Zn was significantly decreased in different stages of breast cancer. Conclusions: Both BChE and Zn are inexpensive and can easily be analyzed and may play a role in the management of breast cancer.",
author = "Rupesh Kumar and Sairoz Razab and Krishnananda Prabhu and Satadru Ray and Bhanu Prakash",
year = "2017",
month = "4",
day = "1",
doi = "10.4103/0973-1482.165869",
language = "English",
volume = "13",
pages = "367--370",
journal = "Journal of Cancer Research and Therapeutics",
issn = "0973-1482",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "2",

}

Serum butyrylcholinesterase and zinc in breast cancer. / Kumar, Rupesh; Razab, Sairoz; Prabhu, Krishnananda; Ray, Satadru; Prakash, Bhanu.

In: Journal of Cancer Research and Therapeutics, Vol. 13, No. 2, 01.04.2017, p. 367-370.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Serum butyrylcholinesterase and zinc in breast cancer

AU - Kumar, Rupesh

AU - Razab, Sairoz

AU - Prabhu, Krishnananda

AU - Ray, Satadru

AU - Prakash, Bhanu

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Context: Even though, a large number of serological, molecular markers have been proposed for breast cancer screening, most of them lack specificity, sensitivity, prognostic value, and cost effectiveness. Butyrylcholinesterase (BChE) and its genes are aberrantly expressed in a variety of human cancers. It has-been linked to tumorigenesis, cell proliferation, and cell differentiation. Zinc (Zn) is a cofactor for superoxide dismutase, an enzyme that protects cellular components against free radical-induced damage and carcinogenesis. Therefore, the aim of present study was to estimate and compare serum BChE and serum Zn levels in healthy controls and biopsy proven breast cancer patients before definitive therapy. Aims: To estimate and compare serum BChE and serum Zn levels in healthy controls and biopsy proven breast cancer patients before definitive therapy. Settings and Design: Serum BChE and Zn were estimated in 46 newly diagnosed (preoperative) female patients with breast cancer and 50 healthy female volunteers. Subjects and Methods: Serum BChE and Zn were estimated by spectrophotometric method. Statistical Analysis Used: Data was expressed as median and inter quartile range. Comparisons between different stages of cancer were done using Kruskal-Wallis test. Results: There was a significant increase in serum BChE and Zn in breast cancer patients compared to controls (P < 0.001). Serum BChE showed a significant increase and Zn was significantly decreased in different stages of breast cancer. Conclusions: Both BChE and Zn are inexpensive and can easily be analyzed and may play a role in the management of breast cancer.

AB - Context: Even though, a large number of serological, molecular markers have been proposed for breast cancer screening, most of them lack specificity, sensitivity, prognostic value, and cost effectiveness. Butyrylcholinesterase (BChE) and its genes are aberrantly expressed in a variety of human cancers. It has-been linked to tumorigenesis, cell proliferation, and cell differentiation. Zinc (Zn) is a cofactor for superoxide dismutase, an enzyme that protects cellular components against free radical-induced damage and carcinogenesis. Therefore, the aim of present study was to estimate and compare serum BChE and serum Zn levels in healthy controls and biopsy proven breast cancer patients before definitive therapy. Aims: To estimate and compare serum BChE and serum Zn levels in healthy controls and biopsy proven breast cancer patients before definitive therapy. Settings and Design: Serum BChE and Zn were estimated in 46 newly diagnosed (preoperative) female patients with breast cancer and 50 healthy female volunteers. Subjects and Methods: Serum BChE and Zn were estimated by spectrophotometric method. Statistical Analysis Used: Data was expressed as median and inter quartile range. Comparisons between different stages of cancer were done using Kruskal-Wallis test. Results: There was a significant increase in serum BChE and Zn in breast cancer patients compared to controls (P < 0.001). Serum BChE showed a significant increase and Zn was significantly decreased in different stages of breast cancer. Conclusions: Both BChE and Zn are inexpensive and can easily be analyzed and may play a role in the management of breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=85021804646&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021804646&partnerID=8YFLogxK

U2 - 10.4103/0973-1482.165869

DO - 10.4103/0973-1482.165869

M3 - Article

AN - SCOPUS:85021804646

VL - 13

SP - 367

EP - 370

JO - Journal of Cancer Research and Therapeutics

JF - Journal of Cancer Research and Therapeutics

SN - 0973-1482

IS - 2

ER -